These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36400409)

  • 1. Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes.
    Treiber G; Guilleux A; Huynh K; Bonfanti O; Flaus-Furmaniuk A; Couret D; Mellet N; Bernard C; Le-Moullec N; Doray B; Jéru I; Maiza JC; Domun B; Cogne M; Meilhac O; Vigouroux C; Meikle PJ; Nobécourt E
    Diabetes Metab; 2023 Mar; 49(2):101409. PubMed ID: 36400409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.
    Zhong ZX; Harris J; Wilber E; Gorman S; Savage DB; O'Rahilly S; Stears A; Williams RM
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):755-762. PubMed ID: 35920656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies.
    Treiber G; Flaus Furmaniuk A; Guilleux A; Medjane S; Bonfanti O; Schneebeli S; Bernard C; Le-Moullec N; Bakiri F; Pholsena M; Rollot O; Vatier C; Jarlet E; Jéru I; Lascols O; Darcel F; Domun B; Venault A; Venault S; Jacquemont ML; Doray B; Maiza JC; Cogne M; Vigouroux C; Nobécourt E
    Eur J Endocrinol; 2021 Aug; 185(4):453-462. PubMed ID: 34292171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irisin levels in LMNA-associated partial lipodystrophies.
    Bensmaïne F; Benomar K; Espiard S; Vahe C; Le Mapihan K; Lion G; Lemdani M; Chazard E; Ernst O; Vigouroux C; Pigny P; Vantyghem MC
    Diabetes Metab; 2019 Jan; 45(1):67-75. PubMed ID: 30165155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial partial lipodystrophy type 2 and obesity, two adipose tissue pathologies with different inflammatory profiles.
    Treiber G; Gonthier MP; Guilleux A; Medjane S; Bonfanti O; Cogne M; Meilhac O; Nobecourt E
    Diabetol Metab Syndr; 2023 Apr; 15(1):77. PubMed ID: 37081489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Spectrum of
    Fernandez-Pombo A; Diaz-Lopez EJ; Castro AI; Sanchez-Iglesias S; Cobelo-Gomez S; Prado-Moraña T; Araujo-Vilar D
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level.
    Hwang YC; Jeong IK; Ahn KJ; Chung HY
    Osteoporos Int; 2012 Apr; 23(4):1337-42. PubMed ID: 21656264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma adiponectin levels in high risk African-Americans with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes.
    Osei K; Gaillard T; Schuster D
    Obes Res; 2005 Jan; 13(1):179-85. PubMed ID: 15761178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study.
    Bianchi C; Miccoli R; Trombetta M; Giorgino F; Frontoni S; Faloia E; Marchesini G; Dolci MA; Cavalot F; Cavallo G; Leonetti F; Bonadonna RC; Del Prato S;
    J Clin Endocrinol Metab; 2013 May; 98(5):2100-5. PubMed ID: 23539736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).
    Mosbah H; Donadille B; Vatier C; Janmaat S; Atlan M; Badens C; Barat P; Béliard S; Beltrand J; Ben Yaou R; Bismuth E; Boccara F; Cariou B; Chaouat M; Charriot G; Christin-Maitre S; De Kerdanet M; Delemer B; Disse E; Dubois N; Eymard B; Fève B; Lascols O; Mathurin P; Nobécourt E; Poujol-Robert A; Prevost G; Richard P; Sellam J; Tauveron I; Treboz D; Vergès B; Vermot-Desroches V; Wahbi K; Jéru I; Vantyghem MC; Vigouroux C
    Orphanet J Rare Dis; 2022 Apr; 17(Suppl 1):170. PubMed ID: 35440056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dexamethasone on glucose homeostasis in normal and prediabetic subjects with a first-degree relative with type 2 diabetes mellitus.
    Taheri N; Aminorroaya A; Ismail-Beigi F; Amini M
    Endocr Pract; 2012; 18(6):855-63. PubMed ID: 22784841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum high-molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus.
    Ozeki N; Hara K; Yatsuka C; Nakano T; Matsumoto S; Suetsugu M; Nakamachi T; Takebayashi K; Inukai T; Haruki K; Aso Y
    Metabolism; 2009 Oct; 58(10):1470-6. PubMed ID: 19592051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2.
    Morel CF; Thomas MA; Cao H; O'Neil CH; Pickering JG; Foulkes WD; Hegele RA
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2689-95. PubMed ID: 16636128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect.
    Foghsgaard S; Vedtofte L; Andreasen C; Andersen ES; Bahne E; Bagger JI; Svare JA; Holst JJ; Clausen TD; Mathiesen ER; Damm P; Knop FK; Vilsbøll T
    Diabetologia; 2017 Jul; 60(7):1344-1353. PubMed ID: 28364253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.
    Vasandani C; Li X; Sekizkardes H; Adams-Huet B; Brown RJ; Garg A
    J Clin Endocrinol Metab; 2020 Jul; 105(7):2132-41. PubMed ID: 32193531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
    Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
    Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. comparative study of glucose homeostasis, lipids and lipoproteins, HDL functionality, and cardiometabolic parameters in modestly severely obese African Americans and White Americans with prediabetes: implications for the metabolic paradoxes.
    Healy SJ; Osei K; Gaillard T
    Diabetes Care; 2015 Feb; 38(2):228-35. PubMed ID: 25524949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal glycemic profiles by CGMS in obese first-degree relatives of type 2 diabetes mellitus patients.
    Madhu SV; Muduli SK; Avasthi R
    Diabetes Technol Ther; 2013 Jun; 15(6):461-5. PubMed ID: 23631606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.